EMR vs TER: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
EMR and TER are similarly sized, but EMR trades noticeably cheaper on forward earnings (20.91x vs 31.83x): the market is paying up for TER's profile and pricing EMR more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
EMR vs TER: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | EMR | TER | What it tells you |
|---|---|---|---|
| Forward P/E | 20.91 | 31.83 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 34.76 | 50.51 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.24 | 1.74 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 64% of range | 69% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 4.13 | 18.31 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: EMR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how EMR and TER affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EMR and TER share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EMR and TER exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Emerson Electric (EMR) do?
Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Over the past several years Emerson has transformed itself from a diversified industrial conglomerate into a more focused automation pure-play, divesting legacy businesses like its commercial and residential climate-technologies unit and acquiring software and measurement assets. Its core products include process control systems, measurement and analytical instruments, valves and actuators, software for plant operations, and test and measurement equipment, much of it sold under brands like DeltaV, Rosemount, Fisher, AspenTech, and NI (National Instruments). Customers span energy, chemicals, life sciences, power, water, food and beverage, and discrete manufacturing. Emerson makes money by selling this hardware and software plus recurring service, software subscriptions, and aftermarket parts, with a meaningful share of revenue tied to keeping installed systems running. The shift toward higher-margin software and recurring revenue, anchored by its majority stake in AspenTech, is central to its strategy. Emerson is headquartered in St. Louis, Missouri.
What does Teradyne (TER) do?
Teradyne designs and sells automated test equipment (ATE) used to verify that semiconductors work before they ship. Its largest business, Semiconductor Test, sells systems like the UltraFLEX and J750 platforms that test system-on-chip (SoC) and memory devices, including the high bandwidth memory and compute processors that power AI data centers. The company makes money mostly from selling these test systems plus recurring service, software, and consumables. Beyond chip test, Teradyne runs a Robotics segment built around Universal Robots (collaborative robot arms) and Mobile Industrial Robots (MiR autonomous mobile robots), plus a smaller Product Test unit, giving it exposure to factory and warehouse automation alongside the core test franchise.
EMR vs TER: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- EMR drivers: Automation pure-play transformation; Software and recurring revenue.
- TER drivers: AI compute and HBM test demand; Memory and HBM share gains.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. For TER, semiconductor test equipment is one of the most cyclical corners of the chip industry, and Teradyne's revenue can swing materially as customers add or pause capacity.
EMR or TER: which should you pick?
EMR vs TER: the full fundamentals
EMR. Emerson trades at a premium to the average industrial, reflecting its transformation into a higher-margin automation and software business and its anchor stake in AspenTech. The market values the recurring-revenue mix, margin expansion, and strong cash generation, while weighing acquisition and integration risk. Its Dividend King status and steady cash flow underpin a quality-industrial profile.
TER. Teradyne's Q1 2026 results set records on AI-driven semiconductor test demand, with Semiconductor Test passing $1 billion in quarterly revenue for the first time. The valuation reflects high expectations for continued AI test demand, so the multiple is elevated relative to the broader semiconductor group. These figures are point-in-time and change with each earnings report and with the stock price, so confirm current numbers before relying on them.
Headline figures (approximate, early 2026): EMR shows revenue (ttm) ~$17-18 billion, operating margin ~20%+, expanding, revenue growth Mid-single-digit underlying, plus acquisitions, software and recurring mix Growing share of revenue; TER shows q1 2026 revenue ~$1.28 billion (up ~87% year over year), segment mix (q1 2026) ~$1,111M Semiconductor Test, ~$91M Robotics, ~$80M Product Test, ai-related revenue ~70% of total revenue tied to AI demand, gross margin ~60.9% (record), non-GAAP operating margin ~37.5%.
The bottom line: EMR vs TER
EMR and TER are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EMR and TER exposure against your real portfolio. It is not an investment adviser.
Wondering how EMR or TER fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Emerson Electric with AI
Connect the broker you already use and ask Walnut's AI how EMR fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between EMR and TER?
+
Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Teradyne designs and sells automated test equipment (ATE) used to verify that semiconductors work before they ship. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is EMR or TER the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, EMR or TER?
+
On forward P/E (as of August 2026), EMR trades at 20.91x and TER at 31.83x, so EMR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both EMR and TER?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of EMR vs TER?
+
EMR: Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. The transformation through large acquisitions like AspenTech and NI carries integration, execution, and valuation risk, and the company took on debt and complexity to fund deals. Competition in automation and industrial software is intense, including from larger and lower-cost rivals. Foreign-exchange effects, supply-chain disruptions, and project delays can pressure results. The stock can be volatile around portfolio moves and macro cycles, and the payoff from the software pivot must still prove out fully. TER: Semiconductor test equipment is one of the most cyclical corners of the chip industry, and Teradyne's revenue can swing materially as customers add or pause capacity. The customer base is concentrated, so a handful of large memory and compute customers drive a large share of orders, and an order delay at any of them can dent a quarter. The robotics business is growing but still small and has historically ramped slowly, so it cannot fully offset a test downturn. Teradyne also competes directly with Advantest, which leads the broader ATE market, so share shifts and pricing pressure are ongoing risks. After a large run-up the shares have at times carried an elevated valuation, which leaves less margin for error if AI test demand normalizes.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell EMR or TER; figures are approximate and dated (as of August 2026). Verify current data before investing.